Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in June
Exelixis, Inc. (Nasdaq: EXEL) will participate in several virtual investor conferences in June 2021. Key presentations include:
- William Blair 41st Annual Growth Stock Conference on June 2 at 5:00pm EDT.
- Goldman Sachs 42nd Annual Global Healthcare Conference on June 9 at 1:20pm EDT.
- BofA Securities 2021 Napa Biopharma Virtual Conference on June 16 at 1:30pm EDT.
Webcast links are available on www.exelixis.com. Exelixis focuses on developing cancer therapies and has several marketed products, including CABOMETYX®.
- None.
- None.
Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following virtual investor conferences in June:
- William Blair 41st Annual Growth Stock Conference: Exelixis is scheduled to present at 5:00pm EDT / 2:00pm PDT on Wednesday, June 2, 2021.
- Goldman Sachs 42nd Annual Global Healthcare Conference: Exelixis is scheduled to present at 1:20pm EDT / 10:20am PDT on Wednesday, June 9, 2021.
- BofA Securities 2021 Napa Biopharma Virtual Conference: Exelixis is scheduled to present at 1:30pm EDT / 10:30am PDT on Wednesday, June 16, 2021.
To access the webcast links, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the presentations to ensure adequate time for any software download that may be required to listen to the webcasts. Replays will also be available at the same location for 14 days.
About Exelixis
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model system genetics, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. Our discovery efforts have resulted in four commercially available products, CABOMETYX® (cabozantinib), COMETRIQ® (cabozantinib), COTELLIC® (cobimetinib) and MINNEBRO® (esaxerenone), and we have entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from our marketed products and collaborations, we are committed to prudently reinvesting in our business to maximize the potential of our pipeline. We are supplementing our existing therapeutic assets with targeted business development activities and internal drug discovery – all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. Exelixis is a member of the Standard & Poor’s (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies. In November 2020, the company was named to Fortune’s 100 Fastest-Growing Companies list for the first time, ranking 17th overall and the third-highest biopharmaceutical company. For more information about Exelixis, please visit www.exelixis.com, follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.
Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks. MINNEBRO is a registered Japanese trademark.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210526006091/en/
FAQ
What investor conferences is Exelixis attending in June 2021?
When is Exelixis scheduled to present at the Goldman Sachs Annual Global Healthcare Conference?
How can I access the webcasts for Exelixis presentations?
What is Exelixis known for in the biotechnology industry?
Is there a replay available for Exelixis’ conference presentations?
